Takeda Announces Publication of Data from SOLSTICE, a Pivotal Phase 3 Trial for LIVTENCITY™ (Maribavir) in Post-Transplant Recipients With Cytomegalovirus (CMV) Infection (Refractory, With or Without Resistance)

Results Of The Global Phase 3 Trial, Now Published In Clinical Infectious Diseases, Show For The Primary Endpoint, LIVTENCITY Was Statistically Superior To Conventional Therapies At Study Week 81 For The Key Secondary Endpoint, LIVTENCITY Was Stati...

Full "IntellAsia: Resources" article